AMGN · News · 20260817N

MariTide Pipeline Progress

AMGEN INC · 2026-08-17 · Importance 23 · Surprise 24

Amgen is continuing development of MariTide, an obesity candidate highlighted in third-party coverage of the company. The report identifies MariTide as a contributor to investor interest in Amgen, but provides no clinical-trial results, launch timing, or market-share data. The item does not disclose customer, geographic demand, or manufacturing implications for the candidate.

Key facts